A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Sponsor

Pfizer (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05363072

Collaborator

(none)

220

Enrollment

5.8

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.

Condition or Disease	Intervention/Treatment	Phase
Renal Cell Cancer Renal Cell Carcinoma Cancer of Kidney Cancer of the Kidney Kidney Cancer Kidney Neoplasms Renal Cancer

Study Design

Study Type:

Observational

Anticipated Enrollment :

220 participants

Observational Model:

Other

Time Perspective:

Retrospective

Official Title:

Registry-based Non-interventional Analysis of Advanced/Metastatic Renal Carcinoma Treatment Patterns and Outcomes in the Hospital District of Southwest Finland.

Anticipated Study Start Date :

May 9, 2022

Anticipated Primary Completion Date :

Nov 1, 2022

Anticipated Study Completion Date :

Nov 1, 2022

Outcome Measures

Primary Outcome Measures

Demographical Characteristics of Participants (treated) [During post-index period (January 2010 - December 2021)]
Demographical Characteristics of Participants (non-treated) [During post-index period (January 2010 - December 2021)]
International Metastatic Database Consortium (IMDC) Risk Group Status at Initiation of Treatment (treated) [During post-index period (January 2010 - December 2021)]
IMDC Risk Group Status at Initiation of Treatment (non-treated) [During post-index period (January 2010 - December 2021)]
Number of Treatments Received in the Advanced/Metastatic Renal Cell Carcinoma (mRCC) Setting [During post-index period (January 2010 - December 2021)]
Number of Treatment Sequences Received in the mRCC Setting [During post-index period (January 2010 - December 2021)]
Time to next treatment (TTNT) [During post-index period (January 2010 - December 2021)]
Overall Survival (OS) [During post-index period (January 2010 - December 2021)]

Secondary Outcome Measures

Number of Participants With Morbidities with Metastatic RCC [During post-index period (January 2010 - December 2021)]
Healthcare Resource Utilization [During post-index period (January 2010 - December 2021)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

For the characteristic group:

Diagnosis of renal cell carcinoma (International Classification of Diseases 10th revision [ICD]-10:64) during 01 January 2010 and 31 December 2021

For the mRCC group:

ICD-10 diagnosis code for metastasis (C77-C79), or
American Joint Committee on Cancer (AJCC) stage 4, or AJCC stage data potentially not available for all patients
Visit to oncologist (specialty code 65) with RCC as main diagnosis, or In Finland, the ICD-10 codes for metastatic disease are rarely used. In contrast, RCC patients visit oncologist, when and only when disease metastasises and therefore, the visit can be used as a proxy to a metastatic disease
Initiation of treatment for mRCC

Exclusion Criteria:

For the characteristic group:

Prevalent mRCC patients (i.e. diagnosis of metastatic RCC before 01 January 2010)
Prevalent mRCC patients (i.e. diagnosis of RCC before 01 January 2010) if there is no records of metastatic disease during 2010-2021